Calcipotriol/Betamethasone Sandoz 50 mikrog/ g / 0.5 mg/ g Νορβηγία - Νορβηγικά - Statens legemiddelverk

calcipotriol/betamethasone sandoz 50 mikrog/ g / 0.5 mg/ g

sandoz - københavn - kalsipotriolmonohydrat / betametasondipropionat - salve - 50 mikrog/ g / 0.5 mg/ g

Calcipotriol/Betamethasone Aristo 50 mikrog/ g / 0.5 mg/ g Νορβηγία - Νορβηγικά - Statens legemiddelverk

calcipotriol/betamethasone aristo 50 mikrog/ g / 0.5 mg/ g

aristo pharma gmbh - kalsipotriolmonohydrat / betametasondipropionat - gel - 50 mikrog/ g / 0.5 mg/ g

Calcipotriol/Betamethasone Orifarm 50 mikrog/ g / 0.5 mg/ g Νορβηγία - Νορβηγικά - Statens legemiddelverk

calcipotriol/betamethasone orifarm 50 mikrog/ g / 0.5 mg/ g

orifarm generics a/s - kalsipotriolmonohydrat / betametasondipropionat - gel - 50 mikrog/ g / 0.5 mg/ g

Calcipotriol Sandoz 50 mikrog/ g Νορβηγία - Νορβηγικά - Statens legemiddelverk

calcipotriol sandoz 50 mikrog/ g

sandoz - københavn - kalsipotriol - salve - 50 mikrog/ g

Rocaltrol 0.25 mikrog Νορβηγία - Νορβηγικά - Statens legemiddelverk

rocaltrol 0.25 mikrog

atnahs pharma netherlands b.v. - kalsitriol - kapsel, myk - 0.25 mikrog

Silkis 3 mikrog/ g Νορβηγία - Νορβηγικά - Statens legemiddelverk

silkis 3 mikrog/ g

galderma nordic ab - kalsitriol - salve - 3 mikrog/ g

Rocaltrol 0.25 mikrog Νορβηγία - Νορβηγικά - Statens legemiddelverk

rocaltrol 0.25 mikrog

2care4 aps - kalsitriol - kapsel, myk - 0.25 mikrog

Rocaltrol 0.25 mikrog Νορβηγία - Νορβηγικά - Statens legemiddelverk

rocaltrol 0.25 mikrog

2care4 aps - kalsitriol - kapsel, myk - 0.25 mikrog

Rocaltrol 0.25 mikrog Νορβηγία - Νορβηγικά - Statens legemiddelverk

rocaltrol 0.25 mikrog

2care4 aps - kalsitriol - kapsel, myk - 0.25 mikrog

Crysvita Ευρωπαϊκή Ένωση - Νορβηγικά - EMA (European Medicines Agency)

crysvita

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - legemidler til behandling av bein sykdommer - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.